Cerus Corp (Cerus) is a biomedical products company that focuses on the field of blood transfusion safety. It develops and commercializes the Intercept blood system, which reduces the risk of transfusion-transmitted infections by inactivating a wide range of pathogens including viruses, bacteria, and parasites present in donated blood. The Intercept blood system is for use with blood components including platelets, plasma, and red blood cells. It is also used to produce intercept fibrinogen complex (IFC), and pathogen reduced plasma and cryoprecipitate. The company markets and sells the Intercept blood system through its direct sales force and distributors in several countries including the US, Europe, the Commonwealth of Independent States (CIS), Latin America, the Middle East, and selected countries in other regions. Cerus is headquartered in Concord, California, the US.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company Cerus Corp
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design, trial status and phase, estimated start and end date.
Reasons to Buy:
- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Table of Contents
- Cerus Corp Company Overview
- Cerus Corp Company Snapshot
- Cerus Corp Pipeline Products and Ongoing Clinical Trials Overview
- Cerus Corp - Pipeline Analysis Overview
- Business Description
- Cerus Corp - Key Facts
- Cerus Corp - Major Products and Services
- Cerus Corp Pipeline Products by Development Stage
- Cerus Corp Ongoing Clinical Trials by Trial Status
- Cerus Corp Pipeline Products Overview
- INTERCEPT Blood System - Red Blood Cells
- INTERCEPT Blood System - Red Blood Cells Product Overview
- INTERCEPT Blood System - Red Blood Cells Clinical Trial
- INTERCEPT Blood System - Whole Blood
- INTERCEPT Blood System - Whole Blood Product Overview
- LyoCryo
- LyoCryo Product Overview
- Next Generation INTERCEPT Blood System
- Next Generation INTERCEPT Blood System Product Overview
- Cerus Corp - Key Competitors
- Cerus Corp - Key Employees
- Cerus Corp - Key Employee Biographies
- Cerus Corp - Locations And Subsidiaries
- Head Office
- Other Locations & Subsidiaries
- Recent Developments
- Cerus Corp, Recent Developments
- Jul 21, 2025: Cerus Corporation Announces Additional Department of Defense Award to Advance Care for Major Hemorrhage in Traumatic Injury
- Jul 02, 2025: Cerus Provides Intercept Red Blood Cell CE Mark Application Update
- May 29, 2025: Cerus Corporation Presents Clinical Data for Intercept Blood System at the 35th Regional International Society of Blood Transfusion Congress in Milan
- May 28, 2025: Cerus Corporation Announces Multiple In-Country Regulatory Approvals for INT200 - Next-Generation INTERCEPT Illumination Device
- Mar 06, 2025: Cerus secures CE mark approval for LED-based illumination device
- Oct 16, 2024: Cerus Provides Updates on INTERCEPT Red Blood Cell Programs in the U.S. and Europe
- Aug 01, 2024: Cerus Announces Second Quarter 2024 Financial Results and Increases Full-Year 2024 Product Revenue Guidance Range
- Mar 26, 2024: Cerus Announces FDA Approval of Extended Shelf Life for Intercept Platelet Processing Sets - Doubling Previous Shelf Life
- Mar 20, 2024: Cerus announces positive results in blood purification trial
- Feb 26, 2024: Growing Demand for Cerus’ INTERCEPT Pathogen Inactivation System for Plasma Drives Additional Investment in Microsize’s Particle Sizing Services.
- Appendix
- Methodology
- About the Analyst
- Contact the Publisher
- Disclaimer
- Cerus Corp Pipeline Products and Ongoing Clinical Trials Overview
- Cerus Corp Pipeline Products by Equipment Type
- Cerus Corp Pipeline Products by Indication
- Cerus Corp Ongoing Clinical Trials by Trial Status
- Cerus Corp, Key Facts
- Cerus Corp, Major Products and Services
- Cerus Corp Number of Pipeline Products by Development Stage
- Cerus Corp Pipeline Products Summary by Development Stage
- Cerus Corp Ongoing Clinical Trials by Trial Status
- Cerus Corp Ongoing Clinical Trials Summary
- INTERCEPT Blood System - Red Blood Cells - Product Status
- INTERCEPT Blood System - Red Blood Cells - Product Description
- INTERCEPT Blood System - Red Blood Cells - A Randomized, Controlled, Single-Blind, 2-Arm Parallel Study to Assess the Recovery and Lifespan of Radiolabeled Autologous INTERCEPT Red Blood Cells Prepared Using the INTERCEPT Blood System for RBCs With AS-1
- INTERCEPT Blood System - Red Blood Cells - Randomized, Double-blind, Controlled, Parallel Group Study with the INTERCEPT Blood System for RBCs in Regions at Potential Risk for Zika Virus Transfusion-transmitted Infections and Treatment Use Open-label Extension Study
- INTERCEPT Blood System - Whole Blood - Product Status
- INTERCEPT Blood System - Whole Blood - Product Description
- LyoCryo - Product Status
- LyoCryo - Product Description
- Next Generation INTERCEPT Blood System - Product Status
- Next Generation INTERCEPT Blood System - Product Description
- Cerus Corp, Key Employees
- Cerus Corp, Key Employee Biographies
- Cerus Corp, Subsidiaries
- Glossary
- Cerus Corp Pipeline Products by Equipment Type
- Cerus Corp Pipeline Products by Development Stage
- Cerus Corp Ongoing Clinical Trials by Trial Status
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Octapharma AG
- MacoPharma International Gmbh
- Kedrion Biopharma Inc
- Terumo BCT Inc
- Grifols SA
